PMID- 20142023
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20211020
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Print)
IS  - 1071-9164 (Linking)
VI  - 16
IP  - 2
DP  - 2010 Feb
TI  - Long-term outcomes with ambrisentan monotherapy in pulmonary arterial 
      hypertension.
PG  - 121-7
LID - 10.1016/j.cardfail.2009.09.008 [doi]
AB  - BACKGROUND: This study evaluated long-term outcomes in patients with pulmonary 
      arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a 
      selective oral endothelin-1 receptor antagonist. METHODS AND RESULTS: Patients 
      who participated in the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 
      3, Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study 
      (ARIES-1) clinical trial and extension phase at our institution were included. 
      Cardiac catheterization, 6-minute walk distance (6MWD), and cardiac magnetic 
      resonance (MRI) data were retrospectively reviewed. Twelve patients with PAH (11 
      idiopathic, 1 fenfluramine) had follow-up from 3 to 5.5 years from the initiation 
      of ARIES-1. Patients received ambrisentan therapy throughout the study period and 
      were on ambrisentan monotherapy for the first 2 years. At year 1, improvements in 
      median mean pulmonary arterial pressure (PA), cardiac output, and pulmonary 
      vascular resistance (PVR) were seen (P = .02, P = .03, P < .01), and the 
      improvement in PVR persisted at 2 years. 6MWD also improved significantly between 
      baseline (350 m) and 1 and 2 years (397 m, P < .01 and 393 m, P = .01). Cardiac 
      MRI results were more varied, with an increase in RV ejection fraction from 29% 
      at baseline to 46% at 2 years (P = .02), but other MRI variables did not improve. 
      CONCLUSIONS: Ambrisentan monotherapy led to improvements in catheterization, 
      6MWD, and RV ejection fraction, and shows promise as a long-term treatment for 
      pulmonary arterial hypertension.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Blalock, Shannon E
AU  - Blalock SE
AD  - Childrens Medical Center Dallas, USA. sblalock98@yahoo.com
FAU - Matulevicius, Susan
AU  - Matulevicius S
FAU - Mitchell, Laura C
AU  - Mitchell LC
FAU - Reimold, Sharon
AU  - Reimold S
FAU - Warner, John
AU  - Warner J
FAU - Peshock, Ronald
AU  - Peshock R
FAU - Torres, Fernando
AU  - Torres F
FAU - Chin, Kelly M
AU  - Chin KM
LA  - eng
GR  - KL2 RR024983/RR/NCRR NIH HHS/United States
GR  - KL2 RR024983-01/RR/NCRR NIH HHS/United States
GR  - UL1 RR024982/RR/NCRR NIH HHS/United States
GR  - UL1 RR024982-01/RR/NCRR NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20091120
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyridazines)
RN  - HW6NV07QEC (ambrisentan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Double-Blind Method
MH  - Exercise Test/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/*mortality/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*administration & dosage
MH  - Pyridazines/*administration & dosage
MH  - Survival Rate/trends
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC2819977
MID - NIHMS151427
EDAT- 2010/02/10 06:00
MHDA- 2010/09/08 06:00
PMCR- 2011/02/01
CRDT- 2010/02/10 06:00
PHST- 2009/06/03 00:00 [received]
PHST- 2009/08/30 00:00 [revised]
PHST- 2009/09/29 00:00 [accepted]
PHST- 2010/02/10 06:00 [entrez]
PHST- 2010/02/10 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - S1071-9164(09)01092-6 [pii]
AID - 10.1016/j.cardfail.2009.09.008 [doi]
PST - ppublish
SO  - J Card Fail. 2010 Feb;16(2):121-7. doi: 10.1016/j.cardfail.2009.09.008. Epub 2009 
      Nov 20.